Pharmedic Pharmaceutical Medicinal Joint Stock Company (Ticker: PMC), traditionally known for its stable cash flow in the Southern market, is entering a volatile period as its financial indicators and brand reputation face significant pressure.
Key highlights of the company’s current operational landscape include:
-
Revenue growth vs. asset depletion paradox: Between 2022 and 2025, while net revenue maintained an upward trend (reaching 546 billion VND in 2025), total assets shrank by approximately 30% to just over 345 billion VND. Notably, owner’s equity also recorded a sharp decline of nearly 187 billion VND during the same period.
-
Debt and inventory pressure: Short-term liabilities surged to 104.5 billion VND by the end of 2025. Furthermore, inventory levels jumped by over 46% within a single year, straining capital turnover and increasing the risks associated with carrying costs.
-
Product quality incident: In early 2026, the Drug Administration of Vietnam fined Pharmedic 70 million VND due to a level 2 quality violation concerning a batch of Diclofen (pain reliever). The entire non-compliant batch was ordered for destruction, dealing a blow to the brand image the company has cultivated over decades.
-
Intense competition in the ethical channel (ETC): With a conservative 2026 profit target of approximately 80 billion VND, Pharmedic continues to struggle in the competitive hospital bidding arena. A unique challenge lies with its largest shareholder, Sapharco, which acts simultaneously as a partner and a direct competitor in medical tenders, leading to overlapping business interests.
Faced with cash flow constraints and increasingly stringent technical barriers in the pharmaceutical industry, Pharmedic is entering a challenging operational cycle that demands decisive adjustments in governance and quality control.